When translating these findings (TG reduction of 0.58 mmol/L) onto the effect size on CAD found in this study, one would expect that lifetime ANGPTL4 inactivation—in a population of normotriglyceridaemic individuals—results in a risk reduction corresponding to a CAD odds ratio of 0.61 (95% CI 0.52–0.72). The gene discussed is ANGPTL4; the disease is coronary artery disorder.